The Board of Directors of Herantis Pharma Plc has appointed Antti Vuolanto (born 1975) as CEO as of 22 July 2022. Frans Wuite will continue as interim CEO of Herantis Pharma Plc until 21 July2022 and as Member of the Board also thereafter. Antti Vuolanto has acted as the Chief Operating Officer of Herantis Pharma Plc since 2018.

Vuolanto graduated as Doctor of Science in Technology at Aalto University, Finland in 2004 in biochemistry and bioprocess technology. He has vast experience in biological drug development, gene therapy products, in-vitro diagnostics, and bioinformatics.